SGMT Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: N/A

Insider Buying (Last 12 Months): $1,231,386.50

Insider Selling (Last 12 Months): $0.00

Sagimet Biosciences Insider Trading History Chart

Sagimet Biosciences Share Price & Price History

^$3.95

▼ -0.2 (-4.82%)

As of 12/6/2023 01:14 PM ET

Days: 30 | 90 | 365

Trading Experts Call It “The Perfect Tesla Trade”

From Wealthpress | Ad

Click here for details,

Sagimet Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/16/2023	David Happel	CEO	Buy	590	$2.35	$1,386.50	590
7/18/2023	Beth C Seidenberg	Director	Buy	46,875	$16.00	$750,000.00	46,875
7/18/2023	Enterprise Associates 13 L New	Major Shareholder	Buy	30,000	$16.00	$480,000.00	3,850,275

New CBOE “special perk” helps traders target income every weekend

From DTI Trader | Ad

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

Check out this training for the full story!

SEC Filings (Institutional Ownership Changes) for Sagimet Biosciences (NASDAQ:SGMT)

Institutional Buying and Selling by Quarter

Sagimet Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2023	RTW Investments LP	400,277	$3.52M	0.1%	N/A	1.875%
11/15/2023	Rock Springs Capital Management LP	738,355	$6.50M	0.2%	N/A	3.458%
11/14/2023	Dumac Inc.	204,123	$1.80M	4.8%	N/A	0.956%
11/13/2023	CHI Advisors LLC	348,842	$3.07M	0.9%	N/A	1.634%
11/13/2023	Northern Trust Corp	41,926	$0.37M	0.0%	N/A	0.196%
11/13/2023	Federated Hermes Inc.	78,000	$0.69M	0.0%	N/A	0.365%
11/13/2023	Silverarc Capital Management LLC	100,000	$0.88M	0.3%	N/A	0.468%
11/13/2023	FMR LLC	2,672,355	$23.52M	0.0%	N/A	12.517%
11/9/2023	Rhumbline Advisers	5,490	$48K	0.0%	N/A	0.026%
11/9/2023	UBS Group AG	2,991	$26K	0.0%	N/A	0.014%
11/8/2023	Charles Schwab Investment Management Inc.	12,562	$0.11M	0.0%	N/A	0.059%
11/7/2023	New York State Common Retirement Fund	6,357	$56K	0.0%	N/A	0.030%
11/6/2023	Victory Capital Management Inc.	17,960	$0.16M	0.0%	N/A	0.084%
11/3/2023	Platinum Investment Management Ltd.	383,913	$3.38M	0.1%	N/A	1.798%
10/31/2023	Teacher Retirement System of Texas	25,000	$0.22M	0.0%	N/A	0.117%

Data available starting January 2016

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Today's Range

Now: $3.95

$3.82

$4.33

50 Day Range

MA: $4.79

$2.23

$9.45

52 Week Range

Now: $3.95

$2.13

$18.33

Volume

156,166 shs

Average Volume

135,922 shs

Market Capitalization

$84.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Sagimet Biosciences?: Sagimet Biosciences' top insider investors include:
Enterprise Associates 13 L New (Major Shareholder)
Beth C Seidenberg (Director)
David Happel (CEO)
Learn More about top insider investors at Sagimet Biosciences.
Who are the major institutional investors of Sagimet Biosciences?: Sagimet Biosciences' top institutional shareholders include:
FMR LLC — 12.52%
Rock Springs Capital Management LP — 3.46%
RTW Investments LP — 1.87%
Platinum Investment Management Ltd. — 1.80%
CHI Advisors LLC — 1.63%
Dumac Inc. — 0.96%
Learn More about top institutional investors of Sagimet Biosciences stock.
Which major investors are buying Sagimet Biosciences stock?: During the last quarter, SGMT stock was bought by institutional investors including:
FMR LLC
Rock Springs Capital Management LP
RTW Investments LP
Platinum Investment Management Ltd.
CHI Advisors LLC
Dumac Inc.
Silverarc Capital Management LLC
Federated Hermes Inc.
In the previous year, these company insiders have bought Sagimet Biosciences stock:
Enterprise Associates 13 L New (Major Shareholder)
Beth C Seidenberg (Director)
David Happel (CEO)
Learn More investors buying Sagimet Biosciences stock.